Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences letairis (ambrisentan — pulmonary arterial hypertension, legacy breakout) ($M) ($M)
Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary
Latest, Q4 2023
36
Period ended Dec 31, 2023
Change on a year earlier
-41.0%
61 in Q4 2022
History
28 quarters
Since Q1 2017
Sources
20
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Letairis (ambrisentan — pulmonary arterial hypertension, legacy breakout) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2023 | Dec 31, 2023 | 36 | -41.0% | Form 10-K (filed 2024-02-23) ↗ |
| Q3 2023 | Sep 30, 2023 | 36 | -16.3% | Form 10-Q (filed 2023-11-07) ↗ |
| Q2 2023 | Jun 30, 2023 | 39 | -20.4% | Form 10-Q (filed 2023-08-04) ↗ |
| Q1 2023 | Mar 31, 2023 | 32 | -25.6% | Form 10-Q (filed 2023-05-03) ↗ |
| Q4 2022 | Dec 31, 2022 | 61 | +24.5% | Form 10-K (filed 2024-02-23) ↗ |
| Q3 2022 | Sep 30, 2022 | 43 | -6.5% | Form 10-Q (filed 2023-11-07) ↗ |
| Q2 2022 | Jun 30, 2022 | 49 | -14.0% | Form 10-Q (filed 2023-08-04) ↗ |
| Q1 2022 | Mar 31, 2022 | 43 | -20.4% | Form 10-Q (filed 2023-05-03) ↗ |
| Q4 2021 | Dec 31, 2021 | 49 | -32.9% | Form 10-K (filed 2024-02-23) ↗ |
| Q3 2021 | Sep 30, 2021 | 46 | -41.0% | Form 10-Q (filed 2022-11-02) ↗ |
| Q2 2021 | Jun 30, 2021 | 57 | -28.7% | Form 10-Q (filed 2022-08-08) ↗ |
| Q1 2021 | Mar 31, 2021 | 54 | -34.9% | Form 10-Q (filed 2022-05-04) ↗ |
| Q4 2020 | Dec 31, 2020 | 73 | -24.0% | Form 10-K (filed 2023-02-22) ↗ |
| Q3 2020 | Sep 30, 2020 | 78 | -35.5% | Form 10-Q (filed 2021-11-03) ↗ |
| Q2 2020 | Jun 30, 2020 | 80 | -60.8% | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2020 | Mar 31, 2020 | 83 | -57.9% | Form 10-Q (filed 2020-05-06) ↗ |
| Q4 2019 | Dec 31, 2019 | 96 | -62.2% | Form 10-K (filed 2022-02-23) ↗ |
| Q3 2019 | Sep 30, 2019 | 121 | -49.8% | Form 10-Q (filed 2019-11-05) ↗ |
| Q2 2019 | Jun 30, 2019 | 204 | -16.4% | Form 10-Q (filed 2019-08-06) ↗ |
| Q1 2019 | Mar 31, 2019 | 197 | -3.4% | Form 10-Q (filed 2020-05-06) ↗ |
| Q4 2018 | Dec 31, 2018 | 254 | +9.0% | Form 10-K (filed 2021-02-25) ↗ |
| Q3 2018 | Sep 30, 2018 | 241 | +13.1% | Form 10-Q (filed 2019-11-05) ↗ |
| Q2 2018 | Jun 30, 2018 | 244 | +6.1% | Form 10-Q (filed 2019-08-06) ↗ |
| Q1 2018 | Mar 31, 2018 | 204 | -3.3% | Form 10-Q (filed 2019-05-08) ↗ |
| Q4 2017 | Dec 31, 2017 | 233 | – | Form 10-K (filed 2019-02-26) ↗ |
| Q3 2017 | Sep 30, 2017 | 213 | – | Form 10-Q (filed 2018-11-06) ↗ |
| Q2 2017 | Jun 30, 2017 | 230 | – | Form 10-Q (filed 2018-08-06) ↗ |
| Q1 2017 | Mar 31, 2017 | 211 | – | Form 10-Q (filed 2018-05-09) ↗ |
Breakdown
What makes up letairis (ambrisentan — pulmonary arterial hypertension, legacy breakout) ($m)
- Letairis (ambrisentan — pulmonary arterial hypertension, legacy breakout) — U.S. sales ($M)36 · Q4 2023
- Letairis (ambrisentan — pulmonary arterial hypertension, legacy breakout) — Europe sales ($M)0 · Q4 2023
- Letairis (ambrisentan — pulmonary arterial hypertension, legacy breakout) — Rest of World sales ($M)0 · Q4 2023
Cite this data
StockData. (2026). Gilead Sciences Letairis (ambrisentan — pulmonary arterial hypertension, legacy breakout) ($M) ($M), quarterly Q1 2017–Q4 2023 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/other_letairis
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.